Cover Image

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters

ABSTRACT: Background: Vitamin D deficiency is a common side effect of imatinib mesylate (IM) therapy. Transporter polypeptides involved in the disposition of IM may be required for maintenance of adequate vitamin D concentrations. Objective: The aim of the present work is to study the association be...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mervat M. Omran, MD (Author), Samia A. Shouman, PhD (Author), Raafat Abdelfattah, MD (Author), Heba S. Moussa, MD (Author), Nadia A. Thabet, Msc (Author), Marwa S. Hamza, PhD (Author)
Format:	Book
Published:	Elsevier, 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013)

Recurrent dermatofibrosarcoma protuberans treated with neoadjuvant imatinib mesylate followed by Mohs micrographic surgery
by: Natalia M. Fontecilla, BA, et al.
Published: (2017)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
by: Hamza MS, et al.
Published: (2022)

Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report
by: Toshihisa Kimura MD, PhD, et al.
Published: (2020)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
by: Xin P, et al.
Published: (2017)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
by: Omar S Din, et al.
Published: (2008)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
by: Bożena Karolewicz, et al.
Published: (2019)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib
by: Alexis Tracy, MD, et al.
Published: (2022)

Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone
by: Joseph H. Butterfield MD
Published: (2021)

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
by: Camillo Porta, et al.
Published: (2011)

Imatinib mesylate-induced cutaneous rash masquerading as pityriasis rosea of Gilbert
by: Prashant Verma, et al.
Published: (2014)

Histological changes of the rat liver after administration of imatinib mesylate:an experimental study
by: Luma Ibrahim Khalel Al-Allaf, et al.
Published: (2019)

Multiple eruptive dermatofibromas secondary to imatinib mesylate in a patient with chronic myeloid leukemia
by: Francisco J Lira-Valero, et al.
Published: (2021)

Concomitant BCR-ABL1 positive chronic myelogenous leukemia emerging in a patient with MPL W515L associated primary myelofibrosis
by: Juan C. Gomez-Gelvez, MD, et al.
Published: (2016)

Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects
by: Joo Young Na, et al.
Published: (2022)

Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
by: Kulkarni Hemant, et al.
Published: (2012)

Development and validation of highly selective method for the determination of imatinib mesylate and dexketoprofen trometamol combination in three different media
by: Ozlem Coban, et al.
Published: (2020)

Serum 25-Hydroxyvitamin D Concentrations in Patients with Type 2 Diabetes Mellitus in Eastern Sudan: A Case-Control Study
by: Ahmed A. Hassan MD, et al.
Published: (2024)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
by: Yan Chen, et al.
Published: (2020)

The effect of radiolabeled nanostructured lipid carrier systems containing imatinib mesylate on NIH-3T3 and CRL-1739 cells
by: Evren Atlihan Gundogdu, et al.
Published: (2020)

Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
by: Emanuelle S. Dal Ponte, et al.
Published: (2017)

Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway
by: Xiaobo Zhang, et al.
Published: (2017)

Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment - Implications to its mechanism of action
by: Goran Gajski, et al.
Published: (2019)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011)

Deep cutaneous candidiasis of the lip in a patient with acute myelogenous leukemia
by: Jose L. Cortez, MD, MS, et al.
Published: (2022)

The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report
by: Moises Harari-Turquie MD, et al.
Published: (2023)

Acute Myelogenous Leukemia With Trisomy 8 and Concomitant Acquired Factor VII Deficiency
by: Leila Moosavi MD, et al.
Published: (2019)

Medication-Related Osteonecrosis of the Jaw Spontaneously Occurred in a Patient with Chronic Myelogenous Leukemia Only by Imatinib: A Report of a Rare Case
by: Makiko Okubo-Sato, et al.
Published: (2021)

CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
by: C. Michael Gibson MS, MD, et al.
Published: (2022)

Cutaneous polyarteritis nodosa presenting as a paraneoplastic phenomenon in chronic myelogenous leukemia
by: Tesia C. Kolodziejczyk, BA, et al.
Published: (2021)

Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature
by: Rohit Gulati, et al.
Published: (2015)

Design, synthesis and biological evaluation of a new thieno[2,3-d]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines
by: Marwa Sharaky, et al.
Published: (2020)

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
by: Patricia Martín-Rodríguez, et al.
Published: (2019)

Colistin Pharmacokinetics in Pediatric Cancer Patients in Egypt
by: Yosr Abou Sedira, et al.
Published: (2022)

The "Golden Hours" Algorithm For the Management of the Multisystem Inflammatory Syndrome in Children (MIS-C)
by: Sanaa Mahmoud MD, PhD, et al.
Published: (2021)

Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate
by: Pei L, et al.
Published: (2020)

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature
by: Gilbert Bader MD, et al.
Published: (2019)